Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer

KRAS is one of the driver oncogenes in non-small-cell lung cancer (NSCLC) but remains refractory to current modalities of targeted pathway inhibition, which include inhibiting downstream kinase MEK to circumvent KRAS activation. Here, we show that pulsatile, rather than continuous, treatment with ME...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Rep
Main Authors: Choi, Hyejin, Deng, Jiehui, Li, Shuai, Silk, Tarik, Dong, Lauren, Brea, Elliott J., Houghton, Sean, Redmond, David, Zhong, Hong, Boiarsky, Jonathan, Akbay, Esra A., Smith, Paul D., Merghoub, Taha, Wong, Kwok-Kin, Wolchok, Jedd D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6719696/
https://ncbi.nlm.nih.gov/pubmed/30995478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2019.03.066
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados